JP2015508284A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508284A5
JP2015508284A5 JP2014548019A JP2014548019A JP2015508284A5 JP 2015508284 A5 JP2015508284 A5 JP 2015508284A5 JP 2014548019 A JP2014548019 A JP 2014548019A JP 2014548019 A JP2014548019 A JP 2014548019A JP 2015508284 A5 JP2015508284 A5 JP 2015508284A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
nucleic acid
homodimeric protein
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014548019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508284A (ja
JP6258864B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/076404 external-priority patent/WO2013092875A1/en
Publication of JP2015508284A publication Critical patent/JP2015508284A/ja
Publication of JP2015508284A5 publication Critical patent/JP2015508284A5/ja
Application granted granted Critical
Publication of JP6258864B2 publication Critical patent/JP6258864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014548019A 2011-12-21 2012-12-20 Hpvに対するワクチン Active JP6258864B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578542P 2011-12-21 2011-12-21
US61/578,542 2011-12-21
PCT/EP2012/076404 WO2013092875A1 (en) 2011-12-21 2012-12-20 Vaccines against hpv

Publications (3)

Publication Number Publication Date
JP2015508284A JP2015508284A (ja) 2015-03-19
JP2015508284A5 true JP2015508284A5 (enExample) 2016-02-18
JP6258864B2 JP6258864B2 (ja) 2018-01-10

Family

ID=47471832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548019A Active JP6258864B2 (ja) 2011-12-21 2012-12-20 Hpvに対するワクチン

Country Status (17)

Country Link
US (1) US9901635B2 (enExample)
EP (2) EP2793937B1 (enExample)
JP (1) JP6258864B2 (enExample)
KR (1) KR102057265B1 (enExample)
CN (1) CN104039833B (enExample)
AU (1) AU2012356969B2 (enExample)
BR (1) BR112014015016B1 (enExample)
CA (1) CA2858963C (enExample)
DK (1) DK2793937T3 (enExample)
ES (1) ES2730718T3 (enExample)
HU (1) HUE043361T2 (enExample)
IL (1) IL233217B (enExample)
PT (1) PT2793937T (enExample)
RU (1) RU2644201C2 (enExample)
TR (1) TR201908199T4 (enExample)
WO (1) WO2013092875A1 (enExample)
ZA (1) ZA201404516B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970466A1 (en) * 2013-03-15 2016-01-20 Vaccibody AS Targeting vaccines for veterinary use
EP3094652B1 (en) * 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CA2957128C (en) * 2014-08-15 2023-09-26 Genexine, Inc. Methods of treating cervical cancer
AU2016309743B2 (en) * 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
AU2017205270B2 (en) * 2016-01-08 2024-01-18 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
EP3678698A1 (en) * 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
JP2023522588A (ja) 2020-04-09 2023-05-31 ナイコード セラピューティクス アルメン アクスイェ セルスカプ 個別化された治療用抗がんワクチン
AU2021261676B2 (en) 2020-04-24 2025-04-24 Genexine, Inc. Method for treating cervical cancer
US20230165952A1 (en) 2020-05-01 2023-06-01 Nykode Therapeutics ASA Betacoronavirus prophylaxis and therapy
KR20230164118A (ko) 2021-03-26 2023-12-01 니코데 테라퓨틱스 에이에스에이 암 치료를 위한 치료 조합
EP4333881A1 (en) 2021-05-03 2024-03-13 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2022238420A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunostimulatory compounds
CA3215057A1 (en) 2021-05-10 2022-11-17 Agnete Brunsvik Fredriksen Co-expression of constructs and immunoinhibitory compounds
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
WO2022238395A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
AU2022275002A1 (en) 2021-05-10 2023-11-09 Nykode Therapeutics ASA Tolerance-inducing constructs and composition and their use for the treatment of immune disorders
US20250049910A1 (en) 2021-11-03 2025-02-13 Nykode Therapeutics ASA Immunogenic Constructs And Vaccines For Use In The Prophylactic And Therapeutic Treatment Of Diseases Caused By SARS-CoV-2
EP4608436A1 (en) 2022-10-25 2025-09-03 Nykode Therapeutics ASA Constructs and their use
EP4615980A1 (en) 2022-11-09 2025-09-17 Nykode Therapeutics ASA Co-expression of constructs and polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
EP1553966B1 (en) * 2002-10-03 2012-08-01 Wyeth Holdings Corporation Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof
US8932603B2 (en) 2003-02-25 2015-01-13 Vaccibody As Modified antibody
SI1576967T1 (sl) * 2004-03-18 2008-02-29 Pasteur Institut Rekombinantni protein, ki nosi epitope humanega papilomavirusa, vstavljene v adenilat ciklazni protein ali njegov fragment, in njegove terapevtske uporabe
EP1846026A4 (en) 2005-01-26 2008-07-02 Univ Johns Hopkins ANTIBODY DNA VACCINE WITH PLASMIDES FOR CODING A MUTATED ONCOPROTEIN ANTIGEN AND CALRETICULIN
AU2011268934B2 (en) 2010-06-25 2015-09-10 Nykode Therapeutics ASA Homodimeric protein constructs

Similar Documents

Publication Publication Date Title
JP2015508284A5 (enExample)
RU2014129788A (ru) Вакцины против hpv
CN108434450B (zh) 基于铁蛋白纳米颗粒的疫苗及其制备方法
JP2013532971A5 (enExample)
Liu et al. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture
JP2015119730A5 (enExample)
JP2012095652A5 (enExample)
RU2013103335A (ru) Конструкции гомодимерных белков
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
BRPI0416393A (pt) molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, métodos para produzir as mesmas, para prevenir infecção por hpv, e para induzir uma resposta imune em um animal, vacina, composições farmacêuticas, e, polipeptìdeo hpv58 l1 isolado e purificado
WO2008098484A1 (en) Recombinant l1 proteins of human papilloma virus and uses thereof
JP2019506175A5 (enExample)
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
JP2014534202A5 (enExample)
JP2016533332A5 (enExample)
BRPI0408639A (pt) molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, método para produzir partìculas semelhantes a vìrus, vacina, composições farmacêuticas, e, métodos para prevenir a infecção por hpv e para induzir uma resposta imune em um animal
JP2015501840A5 (enExample)
CN104710515B (zh) 人乳头瘤病毒l1蛋白突变体及其制备方法
CN102747047A (zh) 人乳头瘤病毒型别杂合病毒样颗粒及其制备方法
JP2014519817A5 (enExample)
JP2026500600A (ja) Hpv感染関連疾患を予防又は治療するためのポリヌクレオチド分子
CN105296521A (zh) 表达可溶性人乳头瘤病毒16亚型l1蛋白的重组质粒及其表达方法
JP2014530224A (ja) ノロウイルス感染に対するワクチンとしての自己集合ペプチドナノパーティクル
Motevalli et al. Supercharged green fluorescent protein delivers HPV16E7 DNA and protein into mammalian cells in vitro and in vivo
JP2013531991A5 (enExample)